Bupropion in Helping Adults Stop Smoking

• ClinicalTrials.gov Identifier: NCT00534001
• Recruitment Status: Completed
• First Posted: September 24, 2007
• Results First Posted: May 30, 2017
• Last Update Posted: May 30, 2017
• Sponsor: Roswell Park Cancer Institute
• Information provided by (Responsible Party): Roswell Park Cancer Institute

Study Description

Brief Summary:

RATIONALE: Bupropion may help people stop smoking by decreasing the symptoms of nicotine withdrawal. Giving bupropion over a longer period of time may be effective in helping people stop smoking.

PURPOSE: This randomized phase II trial is studying how well bupropion works in helping adults stop smoking.

Condition or disease	Intervention/treatment	Phase
Bladder Cancer; Cervical Cancer; Esophageal Cancer; Gastric Cancer; Head and Neck Cancer; Kidney Cancer; Leukemia; Liver Cancer; Lung Cancer; Pancreatic Cancer; Tobacco Use Disorder	Drug: bupropion hydrochloride; Other: placebo	Phase 2

Detailed Description:

OBJECTIVES:

Primary

• Determine the feasibility of conducting a full-scale clinical trial to evaluate whether extending the duration of pre-cessation bupropion hydrochloride enhances smoking cessation, as measured by 3-month prolonged abstinence rates, in adult smokers.

Secondary

• Assess baseline smoking and mood characteristics (nicotine dependence, smoking history, anxiety, and depression).
• Assess measures to address the hypothesized extinction mechanism (subjective effects of smoking, collection of cigarette butts for an assessment of nicotine and tar exposure, craving for smoking, and expectations for the consequences of smoking).
• Assess changes in affective state as measured by Withdrawal Symptoms Checklist and by Positive and Negative Affect Schedule (PANAS) questionnaire.
• Assess side effects, pill counts, and changes in daily smoking rate.
• Assess mental health, personality traits, interpersonal skills, demand simulation, impulsivity, motivation, and perceived stress using validated measures.

OUTLINE: Participants are stratified according to gender. Participants are randomized to 1 of 2 pre-cessation intervention arms.

• Arm I (1-week run-in): Participants receive an oral placebo once or twice daily in weeks 1-3 followed by oral bupropion hydrochloride once or twice daily in week 4. Participants also undergo 90-minute behavioral group counseling sessions once in weeks 1, 2, and 4.
• Arm II (4-week run-in): Participants receive oral bupropion hydrochloride once or twice daily in weeks 1-4. Participants also undergo 90-minute behavioral group counseling sessions once in weeks 1, 2, and 4.

In both arms, participants are asked to quit smoking (target quit date) in week 5. All participants then receive oral bupropion hydrochloride once or twice daily in weeks 5-11 and undergo 90-minute behavioral group counseling sessions once in weeks 5, 7, and 9.

Participants complete questionnaires to collect information on tobacco use history, health habits, depression, anxiety scales/symptoms, and sociodemographics at baseline. Participants also complete a series of validated questionnaires about smoking patterns, smoking satisfaction, mental health, personality traits, interpersonal skills, demand simulation, impulsivity, motivation, and perceived stress at baseline and then periodically during study. Participants undergo saliva sample collection at baseline and then periodically during study. Samples are analyzed for the presence of cotinine. Buccal cells are also collected at baseline for subsequent DNA analyses. Cigarette butts from the first cigarette of the day, including the quit day, are collected during group counseling sessions in weeks 1, 2, 4, and 5 and are assessed for a marker that indicates the amount of nicotine and tar consumed.

After finishing study treatment, participants are followed at 6 and 12 months.

Study Design

• Study Type: Interventional (Clinical Trial)
• Actual Enrollment: 95 participants
• Allocation: Randomized
• Intervention Model: Parallel Assignment
• Masking: None (Open Label)
• Primary Purpose: Other
• Official Title: A Phase II Study of the Effects of Extended Pre-Cessation Bupropion for Smoking Cessation
• Study Start Date: January 2006
• Actual Primary Completion Date: May 2008
• Actual Study Completion Date: July 2015

Arms and Interventions

Arm	Intervention/treatment
Experimental: Arm I (1-week run-in); Participants receive an oral placebo once or twice daily in weeks 1-3 followed by oral bupropion hydrochloride once or twice daily in week 4. Participants also undergo 90-minute behavioral group counseling sessions once in weeks 1, 2, and 4.	Drug: bupropion hydrochloride; Given orally; Other: placebo; Given orally
Experimental: Arm II (4-week run-in); Participants receive oral bupropion hydrochloride once or twice daily in weeks 1-4. Participants also undergo 90-minute behavioral group counseling sessions once in weeks 1, 2, and 4.	Drug: bupropion hydrochloride; Given orally

Outcome Measures

Primary Outcome Measures :

1. Prequit Change in Cigarettes Per Day [ Time Frame: 3-Week PreQuit Drug Manipulation Phase ]
   Prequit Change in Cigarettes Per Day

Secondary Outcome Measures :

1. Abstinence [ Time Frame: 4 weeks ]
   Bioverified 4-week continuous abstinence

Eligibility Criteria

• Ages Eligible for Study: 18 Years to 65 Years (Adult, Older Adult)
• Sexes Eligible for Study: All
• Accepts Healthy Volunteers: No

Criteria

DISEASE CHARACTERISTICS:

• Currently smokes ≥ 15 cigarettes per day for at least 1 year
• Motivated to quit smoking within the next 3 months

PATIENT CHARACTERISTICS:

• Willing to attend clinic visits
• Willing to refrain from nicotine replacement therapy (NRT) use during study participation
• Able to speak and read English fluently
• Has a home telephone and plans to reside in Western New York for the next year
• Not pregnant or nursing
• Negative pregnancy test
• Not planning a pregnancy
• Fertile patients must use effective contraception during and for 3 months after study participation
• No history of chronic renal or hepatic disease
• No history of head trauma or seizure
• No history of a seizure disorder, brain tumor, or CNS tumor
• No history of or currently diagnosed bulimia or anorexia nervosa
• No history of psychotic disorder
• No diabetes requiring oral hypoglycemics or insulin
• No excessive use of alcohol or alcoholism
• No current addiction to opiates, cocaine, or stimulants
• No poorly controlled hypertension (i.e., systolic blood pressure [BP] > 170 mm Hg and/or diastolic BP > 110 mm Hg)
• No allergy to bupropion hydrochloride
• No other surgical or medical condition that may significantly alter absorption, distribution, metabolism, or excretion of bupropion hydrochloride
• No history of noncompliance to medical regimens
• No other clinical contraindication
• No major depressive disorder

PRIOR CONCURRENT THERAPY:

• At least 14 days since prior and no concurrent monoamine oxidase inhibitor
• No recent discontinuation of a benzodiazepine
• No concurrent Hypericum perforatum (St. John's wort)
• No other concurrent drugs containing bupropion hydrochloride (e.g., Wellbutrin or Zyban)
• No concurrent antipsychotics, antidepressants, theophylline, systemic steroids, over-the-counter stimulants or anorectics, or levodopa
• No concurrent active treatment for cancer (e.g., chemotherapy or radiotherapy)

Contacts and Locations

Locations

United States, New York

Roswell Park Cancer Institute

Buffalo, New York, United States, 14263-0001

Sponsors and Collaborators

Roswell Park Cancer Institute

Investigators

• Principal Investigator: Martin Mahoney, MD; Roswell Park Cancer Institute

More Information

• Responsible Party: Roswell Park Cancer Institute
• ClinicalTrials.gov Identifier: NCT00534001
• Other Study ID Numbers: CDR0000565103; I 57805 ( Other Identifier: Roswell Park Cancer Institute )
• First Posted: September 24, 2007
• Results First Posted: May 30, 2017
• Last Update Posted: May 30, 2017
• Last Verified: August 2015

Keywords provided by Roswell Park Cancer Institute:

bladder cancer; cervical cancer; esophageal cancer; gastric cancer; renal cell carcinoma; adult primary liver cancer; non-small cell lung cancer; small cell lung cancer; pancreatic cancer; hypopharyngeal cancer; laryngeal cancer; lip and oral cavity cancer; nasopharyngeal cancer; oropharyngeal cancer; paranasal sinus and nasal cavity cancer; adult acute myeloid leukemia; tobacco use disorder

Additional relevant MeSH terms:

Lung Neoplasms; Pancreatic Neoplasms; Stomach Neoplasms; Uterine Cervical Neoplasms; Urinary Bladder Neoplasms; Esophageal Neoplasms; Liver Neoplasms; Tobacco Use Disorder; Neoplasms; Respiratory Tract Neoplasms; Thoracic Neoplasms; Neoplasms by Site; Lung Diseases; Respiratory Tract Diseases; Digestive System Neoplasms; Endocrine Gland Neoplasms; Digestive System Diseases; Pancreatic Diseases; Endocrine System Diseases; Gastrointestinal Neoplasms; Gastrointestinal Diseases; Stomach Diseases; Head and Neck Neoplasms; Uterine Neoplasms; Genital Neoplasms, Female; Urogenital Neoplasms; Uterine Cervical Diseases; Uterine Diseases; Urologic Neoplasms; Urinary Bladder Diseases